Jaguar Health

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The firm focuses on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Jaguar Health reports revenue growth and eyes cancer therapy market

Jaguar Health's Q1 2024 performance showed revenue growth and improved financial metrics. The company's strategic focus on cancer supportive care and rare diseases positions it for future growth. Challenges include trial result uncertainties and regulatory timelines, but opportunities exist in market expansion and new programs.

Jaguar Health reports revenue growth and promising clinical trial results

Jaguar Health's Q2 2024 earnings call showcases revenue growth, positive clinical trial outcomes, and strategic plans for product launches and FDA discussions. The company's focus on improving patient outcomes and expanding its product reach positions it for future success in the healthcare market.

Jaguar Health reports revenue growth and advances in cancer care

Jaguar Health's Q3 performance reflects revenue growth, successful trial outcomes, and a focus on cancer patient care through innovative products.
While facing challenges in regulatory processes and financial metrics, the company is well-positioned to capitalize on opportunities in rare diseases and oncology.
Overall, Jaguar Health's strategic initiatives and commitment to addressing critical medical needs position it for potential growth and impact in the healthcare sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the Human Health and Animal Health segments. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment includes commercializing prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Proof-of-concept studies of crofelemer in patients with short bowel syndrome (SBS) with intestinal failure or congenital diarrheal disorders planned for 2023 SAN FRANCISCO, CA / ACCESSWIRE / May 1, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Napo Therapeutics, the corporation Jaguar established in Italy in 2021 that focuses on expanding access to the Company's oral botanical drug crofelemer for orphan and rare diseases in Europe, is a Platinum Sponsor of the 9th Annual Elite Ped-GI Congress, which takes place May 4-6, 2023 in Abu Dhabi in the United Arab Emirates. The Annual Elite Ped-GI Congress is designed to provide information about high level, clinically significant updates and comprehensive trends relevant to the practice of pediatric gastroenterological, nutrition and liver disorders.

Napo Therapeutics Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress in Abu Dhabi

91.67% of respondents to a question asking how they see themselves using the product in the future indicated they plan on increasing use of Canalevia®-CA1 over time Canalevia-CA1, Jaguar Health's FDA Conditionally Approved drug for chemotherapy-induced diarrhea (CID) in dogs, is the first and only treatment for CID in dogs to receive any type of approval from the FDA SAN FRANCISCO, CA / ACCESSWIRE / April 27, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced the results of a survey of 26 U.S. veterinary oncologists regarding Canalevia-CA1, the company's U.S. Food and Drug Administration (FDA) conditionally approved prescription drug product for the treatment of chemotherapy-induced diarrhea (CID) in dogs. The study was conducted by Jaguar at the Veterinary Cancer Society (VCS) Collaborative Conference, which took place April 19-22, 2023 in Cancun, Mexico.

U.S. Veterinary Oncologists Participating in a New Survey Prefer Canalevia-CA1 Over the Current Standard of Care

Enrollment expected to complete in mid-Q2 2023 As of March 24, 2023, as previously announced, the Company's cash position was approximately $15.3 million SAN FRANCISCO, CA / ACCESSWIRE / April 11, 2023 / Jaguar Health, Inc. (Nasdaq:JAGX) ("Jaguar" or the "Company") today announced that patient enrollment has surpassed 90% in the Company's pivotal Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy with or without chemotherapy. "Just the week before last - on March 27th - we announced that patient enrollment in OnTarget had reached approximately 80%, and we are very happy to report that enrollment in OnTarget is now already above 90%," said Lisa Conte, Jaguar's president and CEO.

Patient Enrollment Surpasses 90% in Jaguar Health's Pivotal Phase 3 OnTarget Trial of Crofelemer for Cancer Therapy-Related Diarrhea

SAN FRANCISCO, CA / ACCESSWIRE / April 6, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided an update regarding the Company's efforts to identify trading abnormalities in Jaguar's publicly traded Common Stock that could be markers of potential illegal naked short selling. "As we announced in February, Jaguar engaged Shareholder Intelligence Services, LLC (ShareIntel) to help uncover and address potential trading abnormalities in an effort to ensure that those brokering and trading our stock are compliant with FINRA and SEC rules and regulations governing short selling," said Lisa Conte, Jaguar's president and CEO.

Jaguar Health Provides Update on Monitoring Trading Activity to Identify Possible Illegal Short Selling

Canalevia®-CA1 is the first and only treatment for CID in dogs to receive any type of approval from the FDA In December 2022, FDA increased the maximum number of dogs that can be treated annually with a conditionally approved animal drug from 70,000 to 80,000 SAN FRANCISCO, CA / ACCESSWIRE / March 30, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") under its Jaguar Animal Health tradename for the veterinary market, today announced that the Company is exhibiting at the Veterinary Cancer Society (VCS) Collaborative Conference, which takes place April 19-22, 2023 in Cancun, Mexico, as part of ongoing promotional activities for Canalevia-CA1 (crofelemer delayed-release tablets). Canalevia-CA1, the company's U.S. Food and Drug Administration (FDA) conditionally approved prescription drug product for the treatment of chemotherapy-induced diarrhea (CID) in dogs, is available from multiple leading veterinary distributors in the U.S. Effective December 14, 2022, the FDA's Center for Veterinary Medicine increased the maximum number of dogs that can be treated annually with a conditionally approved animal drug from 70,000 to 80,000.

Jaguar Animal Health Exhibiting at Veterinary Cancer Society Collaborative Conference for Canalevia-CA1, the Company's FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs

Jaguar Health, Inc. (NASDAQ:JAGX ) Q4 2022 Earnings Conference Call March 27, 2023 8:00 AM ET Company Participants Lisa Conte - President & Chief Executive Officer Carol Lizak - Chief Financial Officer Ian Wendt - Chief Commercial Officer Conference Call Participants Operator Good morning. Before I turn the call over to management, I would like to remind you that management may make forward-looking statements relating to such matters as contained growth prospects for the company, uncertainties regarding market acceptance of products and the impact of competitive products and pricing, industry trends and product initiatives, including projects in the development stage which may not achieve scientific objectives or be stringent regulatory requirements.

Jaguar Health, Inc. (JAGX) Q4 2022 Earnings Call Transcript

Prescription product net revenue was approximately $11.9 million for the year ended December 31, 2022 versus approximately $4.3 million for the year ended December 31, 2021, an increase of 178.7%. Prescription product net revenue of approximately $3.3 million in Q4 2022 increased 3.4% over Q3 2022 and increased approximately 57% over prescription product net revenue in Q4 2021.

Jaguar Health Reports 2022 Financial Results - Prescription Revenues up 179% to $11.9 Million

Click here to register for webcast Company plans to file its Annual Report on March 24, 2023 on Form 10-K for the fiscal year ended December 31, 2022 SAN FRANCISCO, CA / ACCESSWIRE / March 24, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company investor webcast scheduled for Monday, March 27, 2023 to review fourth-quarter 2022 financials and provide corporate updates will now take place at 8:00 a.m. Eastern Daylight Time instead of 8:30 a.m.

Jaguar Health Announces Time Change for March 27th Investor Webcast to 8:00 AM EDT

SAN FRANCISCO, CA / ACCESSWIRE / March 23, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") and its wholly owned subsidiary Napo Pharmaceuticals (Napo) today announced that Dr. Kelly Shanahan, a former clinician and a metastatic breast cancer patient who is now a full-time independent patient advocate, has joined the Jaguar/Napo Scientific Advisory Board (SAB). "We are very pleased that Dr. Shanahan has joined our SAB," said Pravin Chaturvedi, PhD, Napo and Jaguar's Chair of the Scientific Advisory Board and Chief Scientific Officer.

Leading Cancer Patient Advocate Kelly Shanahan, M.D., Joins Jaguar Health's Scientific Advisory Board

Click here to register for webcast Company plans to file its Annual Report on March 24, 2023 on Form 10-K for the fiscal year ended December 31, 2022 SAN FRANCISCO, CA / ACCESSWIRE / March 21, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Monday, March 27, 2023 at 8:30 a.m. Eastern Daylight Time to review fourth-quarter 2022 financials and provide corporate updates.

Jaguar Health to Hold Investor Webcast Monday, March 27th at 8:30 AM EDT Regarding Q4 2022 Financials & Corporate Updates

The United Nations General Assembly's theme for the 2023 International Day of Forests is "Forests and Health" as Jaguar collaborates with communities in the Amazonia rainforest to ethically source the active ingredient in its FDA approved botanical drug SAN FRANCISCO, CA / ACCESSWIRE / March 15, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company, in advance of International Day of Forests, which takes place March 21, 2023, has achieved an important milestone related to the health of forest ecosystems, people, and communities in the Peruvian Rainforest. For well over a decade, the Company has been collaborating with tropical forest peoples and communities to collect the latex of the Dragon's Blood tree (Croton lechleri), from which crofelemer, the active pharmaceutical ingredient in the Company's FDA-approved oral botanical drug, is extracted and purified.

Jaguar Health Celebrates U.N. International Day of Forests with Milestone of Providing Income to 20,000+ People Living in Tropical Rainforest Communities

AI technology is expected to help make it faster and easier for Mytesi® patients to start and stay on the drug SAN FRANCISCO, CA / ACCESSWIRE / March 13, 2023 / Jaguar Health, Inc. (Nasdaq:JAGX) ("Jaguar" or the "Company") today announced that the Company is developing an artificial intelligence-powered web portal for U.S. healthcare professionals to support patient access to Mytesi (crofelemer), the Company's FDA-approved antidiarrheal prescription drug indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy. "We remain committed to reducing access and reimbursement barriers for Mytesi patients.

Jaguar Health Leveraging AI to Support Patient Access to Mytesi, the Company's FDA-Approved Prescription Drug

Presentation will cover Jaguar and Napo Therapeutics' focus on development and commercialization of crofelemer for short bowel syndrome (SBS) and congenital diarrheal disorders (CDD) Crofelemer has received orphan drug designation from the FDA and the European Medicines Agency for both SBS and a specific genetic abnormality resulting in a CDD condition SAN FRANCISO, CA / ACCESSWIRE / March 2, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Lisa Conte, the Company's founder, president, and CEO, is scheduled to present at the BioTrinity 2023 conference in London on Tuesday, April 25, 2023 during the R&D Spotlight session on Rare Diseases. Ms. Conte is also Chairman of the Board of Napo Therapeutics, the corporation Jaguar established in Italy in 2021 with a mission to expand crofelemer access in Europe for the treatment and management of targeted orphan and rare disease indications.

Jaguar Health to Present at BioTrinity 2023 Conference's R&D Spotlight on Rare Diseases

Crofelemer was previously granted Orphan Drug Designation by the FDA for short bowel syndrome SAN FRANCISCO, CA / ACCESSWIRE / February 28, 2023 / Jaguar Health (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to crofelemer for the indication of microvillus inclusion disease (MVID), a rare congenital diarrheal disorder (CDD) condition, following review of the ODD application the Company submitted to the FDA. "This is another very welcome development for our oral botanical drug, crofelemer, a new molecular entity that now holds four orphan designations, as crofelemer previously received ODD for MVID from the European Medicines Agency (EMA) and for short bowel syndrome (SBS) from both the FDA and the EMA," said Lisa Conte, Jaguar's president and CEO.

FDA Grants Orphan Drug Designation to Jaguar Health for Crofelemer for Microvillus Inclusion Disease (MVID), a Second Rare Disease Indication in the US

Company's IP estate includes approximately 200 patents issued and pending SAN FRANCISCO, CA / ACCESSWIRE / February 23, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 16/617,466, titled Methods And Compositions For Treating Bile Acid Diarrhea, Diarrhea Associated With Small Intestine Resection Or Gallbladder Removal, And Short Bowel Syndrome.

Jaguar Health Receives Notice of Allowance for U.S. Patent for Lead FDA Approved Drug Crofelemer

Addition of OnTarget trial sites in Europe, South America and Asia has significantly accelerated enrollment, which is expected to complete in Q2 2023 Adoption of premier digital health technology for data collection facilitates operational efficiency of this global trial SAN FRANCISCO, CA / ACCESSWIRE / February 21, 2023 / Jaguar Health, Inc. (Nasdaq:JAGX) ("Jaguar" or the "Company") today announced that patient enrollment has reached approximately 75% in the Company's pivotal Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy, with or without chemotherapy. Target trial enrollment of 256 patients is expected to complete in the second quarter of 2023.

Jaguar Health Achieves Approximately 75% Enrollment in Pivotal Phase 3 OnTarget Trial of Crofelemer for Cancer Therapy-Related Diarrhea

This closing on funds from SPRIM Global Investments, a healthcare-focused international venture capital firm, was completed at a fully diluted valuation of approximately €55 million Jaguar currently owns approximately 73.5% of Napo Therapeutics Napo Therapeutics' mission is to provide access to Jaguar's proprietary first-in-class plant-based medicine crofelemer in Europe to address significant rare disease indications SAN FRANCISCO, CA / ACCESSWIRE / February 9, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced a closing in a private placement financing round for Napo Therapeutics, the Italian corporation established by Jaguar in Milan, Italy in 2021 that focuses on expanding crofelemer access in Europe. "As majority shareholders of Napo Therapeutics, we are very pleased with the closing of this initial investment which is part of a larger round of Napo Therapeutics funding expected to close before March 31, 2023.

Jaguar Health Announces Initial Close in Private Placement Financing Round for Napo Therapeutics S.p.A.

Beyond Meat

Carvana

FuboTV

Intel

Lucid Group

Summit Wireless Technologies Inc

We're out of January and finally settling into the 2023 year. After ending 2022 in the red, all the major indices are showing gains through the first month of the year.

7 F-Rated Stocks to Sell in February

Tao Wang, SynWorld's General Manager and a long-term shareholder of restricted Jaguar stock, fully aligned on termination decision SAN FRANCISCO, CA / ACCESSWIRE / February 1, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") and SynWorld Technologies Corporation (SynWorld) today announced that the two companies have mutually agreed to terminate the exclusive license and services agreement (the "Canalevia Agreement") executed in June 2022 for the treatment of diarrhea in dogs in the China market with Jaguar's Canalevia® (crofelemer delayed-release tablets) prescription drug product effective January 31, 2023. "Given Jaguar's sharp strategic focus in 2023 on human drug development - specifically on our Phase 3 pivotal OnTarget trial of crofelemer for our core follow-on indication of prophylaxis of cancer therapy-related diarrhea (CTD) and our crofelemer development efforts for the rare disease indications of short bowel syndrome (SBS) and congenital diarrheal disorders (CDD) - we and SynWorld have agreed that it makes sense to terminate the Canalevia Agreement at this time," said Lisa Conte, Jaguar's founder, president, and CEO.

Jaguar Health & SynWorld Technologies Mutually Agree to Terminate License and Commercialization Agreement for Canalevia for Treatment of Diarrhea in Dogs in China Given Jaguar's 2023 Focus on Human Drug Development

SAN FRANCISCO, CA / ACCESSWIRE / February 1, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that it has entered into a service agreement with Shareholder Intelligence Services, LLC (ShareIntel), a leading compliance driven SAAS platform, to track market participants and analyze share ownership data in Jaguar's publicly traded Common Stock ("JAGX") on Nasdaq for SEC and FINRA market compliance. "Illegal short selling practices are a form of market manipulation that can harm investors and public companies by artificially and systematically depressing stock prices, increasing the cost of capital, restricting growth, and jeopardizing compliance with Nasdaq listing requirements.

Jaguar Health Engages Shareholder Intelligence Services, LLC (ShareIntel) to Monitor Trading Activity in Effort to Identify Possible Illegal Short Selling

SAN FRANCISCO, CA / ACCESSWIRE / January 30, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that it has entered into a consulting agreement with Andrew Mulberg, M.D. to enhance the company's regulatory expertise.

Jaguar Health Engages Former FDA Gastroenterology Division Deputy Director Andrew Mulberg, M.D. to Bolster Company's Regulatory Expertise

Rare disease indications are the sole focus of Napo Therapeutics, the corporation established by Jaguar in Italy in 2021, with an initial focus on short bowel syndrome Jaguar to take the lead on microvillus inclusion disease in the U.S., with the Company intending to submit an Investigational New Drug (IND) application to the FDA for this ultra-rare disease in 1H 2023 SAN FRANCISCO, CA / ACCESSWIRE / January 26, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided updates regarding the Company's focus on rare and orphan disease indications: short bowel syndrome (SBS), microvillus inclusion disease (MVID), and cholera. Rare disease indications are the sole focus of Napo Therapeutics, the corporation established by Jaguar in Italy in 2021, with an initial focus on SBS.

Jaguar Health Provides Updates Regarding Company's Focus on Rare and Orphan Disease Indications in the U.S. & Europe

Milestone supports the expansion of manufacturing volume required for potential additional indications for crofelemer, including cancer therapy-related diarrhea Crofelemer API (active pharmaceutical ingredient) manufactured by Indena can now be used by Jaguar for development work Patient enrollment expected to complete in Q2 2023 for company's pivotal Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy SAN FRANCISCO, CA / ACCESSWIRE / January 25, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the required procedure of registering the source of the active pharmaceutical ingredient (API) of crofelemer with the Agenzia Italiana Del Farmaco (AIFA), the Italian Medicines Agency, has been successfully completed. Resultingly, batches of crofelemer API manufactured by Milan, Italy-based Indena S.P.A.

Jaguar Health Announces Completion of Key Milestone in Process of Establishing Indena S.p.A. as a Reliable Approved Crofelemer Manufacturer

Jaguar Health (NASDAQ: JAGX ) stock is on the move Monday as investors seek answers to its massive 6,800% gain this morning. For the record, JAGX stock didn't actually rally almost 7,000% in Monday morning trading.

Is Jaguar Health (JAGX) Stock Really Up 6,800%?

Magdalena Biosciences is focused on developing novel, natural prescription medicines derived from plants for mental health indications including attention-deficit/hyperactivity disorder (ADHD) in adults SAN FRANCISCO, CA / ACCESSWIRE / January 23, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the board of directors has been established for Magdalena Biosciences, Inc., the joint venture recently formed by Jaguar and Filament Health Corp. (NEO:FH, OTCQB:FLHLF) to develop novel, natural prescription medicines derived from plants for mental health indications including attention-deficit/hyperactivity disorder (ADHD) in adults. Magdalena board members include Jaguar Founder, President, and Chief Executive Officer Lisa Conte, Filament Co-Founder and Chief Executive Officer Benjamin Lightburn, and Jack Wielebinski, Fund Operating Officer, One Small Planet, LLC.

News for Jaguar Health Stock (JAGX)